Recently, Morgan Stanley Capital International (MSCI), the world’s reputable environmental, social, and governance (ESG) rating institutions, released its 2024 ESG ratings in which Hansoh Pharma achieved an AA rating for the second year in a row, keeping the company at the forefront of the industry.
In this year’s MSCI rating report, Hansoh Pharma advanced across two key issues: "Toxic Emissions and Waste" and "Corporate Behavior," making it a global ESG leader in these two areas for the first time. Now, Hansoh Pharma is recognized as an ESG leader in five key issues, including "Product Safety & Quality," "Corporate Governance," and "Access to Healthcare.”
As one of the world’s most well-recognized ESG index rating institutions, MSCI ratings have become a popular benchmark for investments in international capital markets. Being awarded an AA rating for two years consecutive manifests Hansoh Pharma’s strong commitment to sustainable development and also highlights the company’s exceptional performance in corporate governance, scientific research and innovation, product quality, accessible healthcare, human capital development, community welfare, sustainable supply chain, and low-carbon environmental initiatives.
The company’s ESG governance system is widely acknowledged by global ESG rating agencies and professional medical media. In 2024, Hansoh Pharma was once again included inS&P Global Sustainability Yearbook 2024 and S&P Global Sustainability Yearbook 2024 (China Edition), as the highest-scoring company among industry peers in Chinese mainland. Additionally, the company was placed among the Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Large-Cap) by Healthcare Executive for three consecutive years, and ranked first in the "Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies”.
Fulfilling social responsibilities is key for companies to achieve sustainable development, and continually generating value long term is beneficial for all parties concerned. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will actively respond to the United Nations Sustainable Development Goals, continuously implement advanced ESG practices and make greater contributions to the long-term development of the global economy, environment, and society.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
